Denmark has halved its 2025 economic growth forecast from 3% to 1.4% due to a slowdown at Novo Nordisk, the maker of popular diabetes drugs Ozempic and Wegovy. This decline is attributed to weaker expectations for the pharmaceutical giant, increased competition, and inventory buildup. Despite the slowdown, there are long-term positive projections for GLP-1 drugs, which could boost GDP and reduce obesity-related health issues. The global market for obesity drugs is expected to grow significantly by 2035. Teljes cikk (Euronews.com)